艾伏尼布副作用是什么,需要注意哪些事项?

Ivosidenib is a potent and highly selective oral "first-in-class" IDH1 inhibitor, also known as ivosidenib, Tibsovo, which can be used not only for adult patients with IDH1-mutated cholangiocarcinoma, but also for the treatment of adult patients with acute myeloid leukemia (AML) with IDH1 mutations. It is well tolerated and has a controllable safety profile. It has attracted the attention of patients once it was launched. So, what are the side effects of Avonib and what should we pay attention to?

What are the side effects of ivonib?

Although the therapeutic effect of ivonib is remarkable, it also has many adverse reactions, such as edema, nausea, fatigue, leukocytosis, joint pain, diarrhea, dyspnea, rash, fever, cough, constipation, mucositis, prolongation of QT on electrocardiogram, etc. The manifestations of adverse reactions are also different depending on the patient's constitution and symptoms. In addition, the laboratory abnormalities of ivonib include: decreased phosphate, decreased hemoglobin, decreased calcium, increased uric acid, decreased potassium, increased alkaline phosphatase, decreased sodium, decreased magnesium, increased aspartate aminotransferase, increased creatinine, etc.

What should you pay attention to with Avonib?

During treatment with ivonib, it should be noted that leukemia patients are prone to acute myeloid leukemia differentiation syndrome after treatment, including non-infectious leukocytosis, peripheral edema, fever, dyspnea, pneumonia, pericardial effusion, pleural effusion, hypotension, hypoxia, pulmonary edema, rash, fluid overload, tumor lysis syndrome and elevated creatinine.

During the use of ivosidenib, it is also necessary to note that QT (QTc) prolongation and ventricular arrhythmias may occur in treated patients; for patients who develop QTc interval prolongation accompanied by signs or symptoms of life-threatening arrhythmias, ivosidenib needs to be permanently discontinued; patients taking this product should be monitored for new signs or symptoms of motor and/or sensory neuropathy.

Ivonib is a small molecule inhibitor that targets mutant isocitrate dehydrogenase 1 (IDH1) enzyme. The recommended dose of ivonib is 500 mg taken orally once a day. Patients must follow the doctor's instructions and do not change the dosage and usage at will to avoid intolerance reactions.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: